Add a New Bulls Reason

Company: Abbott Laboratories (ABT)
Current price:
Headline: (100 character max)
Analysis:
Cancel
100%
agree
35 votes

  New Medicare reform has led to the coverage Humira

New Medicare reform has led to the coverage Humira, Abbott's top selling RA medication. This will lead to an increase in sales and allow Humira to shift market share away from its new competitors in the Medicare market, Remicade and Enbrel.

(100 character max) Cancel
100%
agree
5 votes

  Abbott is awaiting FDA approval for additional indications of Humira

Abbott is awaiting FDA approval for additional indications of Humira. After excellent clinical trials for new indications, Humira will be a threat to the existing competition. If Humira is approved for more indications, its sales are expected to double within the next few years.

(100 character max) Cancel
100%
agree
5 votes

  Xience V drug-eluting stent has had successful late-stage clinical trials

Abbott's Xience V drug-eluting stent has had very successful late-stage clinical trials. If approved by the FDA, Xience V is projected to take over the multi-billion dollar DES market and prove to be highly profitable to Abbott.

(100 character max) Cancel
100%
agree
2 votes

  Cash, cash, cash

Abbott has significant amounts of cash for strategic acquisitions and to support R&D - all while maintaining healthy dividends.

(100 character max) Cancel
100%
agree
1 votes

  Abbott to Buy Solvay Drug Unit for $7 Billion

The proceeds will be reinvested in external and organic growth with a sharp focus on long term value creation. Abbott sees the partnership as a way to expand into emerging markets in Eastern Europe and Asia, where Abbott had limited presence

Reference

"Abbott to Buy Solvay Drug Unit for $7 Billion" Article from Wall Street Journal

(100 character max) Cancel
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki